

Three assets. One diligence budget.

THE FICTIONAL SCENARIO

A fictional biotech team has capacity to advance one asset into detailed diligence. The team compares three hypothetical programs using the same criteria. The scores below are invented to demonstrate the output format; they are not clinical probabilities, valuations or investment recommendations.

ILLUSTRATIVE ASSET SCREENING MATRIX

Criterion / weight	Asset A	Asset B	Asset C
Evidence maturity / 30%	4	3	2
Differentiation / 25%	3	4	5
Execution feasibility / 20%	4	2	2
Commercial rationale / 15%	3	4	4
Mandate fit / 10%	5	3	2
Weighted score / 5	3.70	3.20	3.05

Scale: 1 = weak, 3 = moderate, 5 = strong. Weighted score = sum of criterion score x weight. All weights total 100%. Scores and weights are fictional assumptions.

WHAT THE EXAMPLE SUGGESTS

Under these assumptions, Asset A is the first diligence candidate. This is a screening priority only: an unresolved evidence gap can override the numerical rank.

If Asset A's evidence-maturity score falls from 4 to 2 after source review, its total falls from 3.70 to 3.10. Asset B then leads at 3.20. This shows why evidence validation precedes a commitment.

Turn the ranking into a diligence agenda.

Asset A | Validate the apparent lead

Request the full evidence package and assess reproducibility, safety context and the next development decision.

Asset B | Resolve the execution constraint

Test whether manufacturing, team capability or financing dependencies explain the lower feasibility score.

Asset C | Test the differentiation thesis

Ask what evidence would establish a meaningful advantage and whether the development path is credible.

EXAMPLE OUTPUTS AND CHECKPOINTS

- 1. Evidence pack** - Dated source register, comparable asset profiles and explicit gaps.
- 2. Challenge session** - Review the ranking with decision makers and record counterarguments.
- 3. Decision checkpoint** - Advance, pause or reject each diligence track against agreed conditions.

TO SCOPE A REAL ENGAGEMENT

Asset summaries; development-stage evidence; available clinical or preclinical reports; target product profile; mandate and decision deadline.

A screening score is a discussion aid. It does not establish safety, efficacy, commercial viability or an investment value.

Discuss your project: contact@orqalis.com

All scenarios, organizations, scores and schedules are illustrative. This is not completed client work. Scope, timing and deliverables are agreed for each engagement.